JSKN-033

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameJSKN-033
Drug Alias Name恩维达JSKN033JSKN-033JSKN-003/Envafolimab
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody) +[4] 
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonistsProgrammed death-ligand 1 blockersDNA topoisomerase inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2Programmed death-ligand 1DNA topoisomerase
Therapy Area/IndicationsSolid tumoursUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell Lung +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsYes JSKN-003Envafolimab
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesJiangsu Alphamab Biopharmaceuticals Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesAlphamab OncologyJiangsu Alphamab Biopharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsSolid tumoursNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A